Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

319
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
319
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

806
Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
806
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

712
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
712
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

597
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
597

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endoscopic visual cues of intrarenal pressure during ureteroscopy: in vivo porcine studies.

BJU international·2026
Same author

Fiber-to-stone distance and fragment size with holmium laser lithotripsy.

Urolithiasis·2026
Same author

Intrarenal pressure response to suction during ureteroscopy with a flexible and navigable suction sheath: in vivo porcine studies.

Urolithiasis·2026
Same author

Flexible and Navigable Suction Ureteral Access Sheaths for the Treatment of Urolithiasis: Systematic Review and Meta-analysis.

European urology focus·2025
Same author

Direct in-scope suction (DISS) ureteroscopy: techniques, outcomes and future directions.

BJU international·2025
Same author

Improved control of renal pelvis pressure using a prototype fluid management system incorporating ureteroscope pressure feedback.

Urolithiasis·2025
Same journal

Pediatric andrology: bridging pediatric urology and reproductive medicine.

Current opinion in urology·2026
Same journal

Current impact of simulation-based surgical training in urology: a review from the European School of Urology and the European Association of Urology Endourology Section.

Current opinion in urology·2026
Same journal

Personalized therapy in metastatic hormone-sensitive prostate cancer: a 2026 update on navigating therapeutic complexity.

Current opinion in urology·2026
Same journal

Role and relevance of genetic testing in patients with kidney stones: a review from EAU Section of Endourology.

Current opinion in urology·2026
Same journal

Advances in evaluating and delivering nontechnical skills training: The use of simulation, robotics, artificial intelligence and virtual reality.

Current opinion in urology·2026
Same journal

Educating for a sustainable future: faculty and student perspectives and a review of environmental sustainability in medical education - an EAU endourology study.

Current opinion in urology·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K

New technologies in benign prostatic hyperplasia management.

William W Roberts1

  • 1Department of Urology and Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.

Current Opinion in Urology
|February 10, 2016
PubMed
Summary
This summary is machine-generated.

New technologies for benign prostatic hyperplasia (BPH) offer less invasive treatment options. These advancements aim to improve upon traditional transurethral resection of the prostate (TURP) with faster, office-based procedures.

More Related Videos

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K

Related Experiment Videos

Last Updated: Mar 26, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K
Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser
05:28

Enucleation of the Prostate for the Treatment of Benign Prostatic Hyperplasia Using a 980 nm Diode Laser

Published on: May 5, 2020

2.9K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.6K

Area of Science:

  • Urology
  • Medical Technology
  • Prostate Health

Background:

  • Transurethral resection of the prostate (TURP) is the gold standard for benign prostatic hyperplasia (BPH).
  • Increasing patient age and complexity necessitate less morbid BPH treatment alternatives.
  • Advancements in understanding prostate pathophysiology drive new BPH technology development.

Purpose of the Study:

  • To review emerging BPH technologies and their clinical data.
  • To emphasize unique technological features, procedural effectiveness, and safety.
  • To assess the potential impact of new technologies on current BPH treatment paradigms.

Main Methods:

  • Review of available clinical data for new BPH technologies.
  • Emphasis on technologies utilizing steam injection, high-pressure saline, or focused acoustic energy.
  • Exploration of targeted cell death methods like embolization and injectable biological therapies.

Main Results:

  • New technologies aim to reduce urinary obstruction by reshaping the prostate.
  • Methods include thermal dose delivery via steam, mechanical disintegration via saline or acoustic energy.
  • Targeted therapies focus on arterial supply (embolization) or prostate cells (injectable biologics).

Conclusions:

  • Several new BPH technologies are in development.
  • These innovations move toward an ideal BPH therapy: definitive, rapid, office-based, and minimally invasive.
  • Future treatments may offer improved outcomes with reduced patient morbidity.